While the past year has seen a fading in the IPO market, the volume of deal flow and valuations for M&A remain high. Many of the largest industry members have strong cash positions, and most analysts continue to expect pipeline enhancement via acquisition. As political forecasts suggest high potential for tax reform and other changes in how international deals might be reviewed, there are multiple ways 2017 could be a great year or a terrible year for biopharma M&A. This session will talk through the likely and extreme scenarios, as well as provide insight on what signs to watch for from Washington and Wall St. along the way.
Session attendees will hear updated findings from two unique, forward-looking measures of deal-making in the industry the inVentiv Health Consulting Dealmakers' Intentions Study and the BIO One-on-One Partnering Forecast. Based on a survey of more than 150 industry executives and business development professionals, Dealmakers' Intentions provides insight into what will likely drive the industry's partnering and M&A efforts moving forward and the implications for deal-making over the next year or more. Now in its ninth year, analysis will include year-over-year trends, deal metrics and broader M&A data.
Additionally, a highly distinguished panel of deal-makers will explore the impact these market forces will have on pharmaceutical and biotech companies as they strive to make the next big deal.
Session ID: 24884